Australia Artificial heart Market Overview, 2031

Australia’s artificial kidney-heart market sits at the intersection of renal replacement and advanced cardiac support, with performance shaped by rising chronic kidney disease and cardiovascular prevalence, higher healthcare expenditure, and improved care pathways across hospitals and home-based settings. Growth is driven by the shift toward portable, patient-centric solutions, expanding telehealth, and supportive reimbursement for dialysis and cardiac devices, while the purpose and benefits centre on reducing hospital dependency, enhancing quality of life, and bridging donor organ shortages through bioartificial and mechanical technologies. Historically, the market evolved from mid-20th-century dialysis and heart-lung machines to sophisticated haemodialysis, peritoneal dialysis, ventricular assist devices (VADs), and total artificial heart prototypes, expanding the scope of products from clinic-based systems to wearable and implantable devices. The technology scope includes biocompatible membranes, sorbent-based dialysis regeneration, continuous renal replacement therapy, VADs with magnetically levitated pumps, and AI-enabled remote monitoring that personalizes therapies. Market components span device manufacturers, nephrology and cardiology clinics, integrated care programs, payors, and research institutes. Policies emphasize rigorous safety and clinical evidence under the TGA framework, with procurement shaped by hospital networks and public-private initiatives. Challenges include high R&D costs, regulatory complexity, rural access gaps, workforce training, and patient adoption hurdles for novel implantables. Cultural trends show preference for home therapies, flexible treatment schedules, and digital follow-up, with customer behavior oriented toward reliability, low-maintenance devices, and transparent outcome data. Australia’s market connects with the parent global landscape, drawing innovation from Asia-Pacific’s rapid growth in artificial heart technologies and leveraging global scale in cardiovascular devices to inform domestic adoption and procurement practices.

According to the research report, "Australia Artificial heart Overview, 2031," published by Bonafide Research, the Australia Artificial heart is anticipated to grow at more than 10.2% CAGR from 2026 to 2031.Australia’s artificial heart market features global leaders and local innovators, with competition spanning VADs, investigational total artificial hearts, and perioperative support devices. Local players such as Brisbane-based BiVACOR advance magnetically levitated, compact total artificial heart designs through university-hospital collaborations and multinational trials, positioning on durability, hemocompatibility, and physiologic flow control as a USP. Product portfolios range from implantable mechanical circulatory support to extracorporeal devices and integrated remote monitoring services business models combine direct hospital partnerships, distributor networks, clinical trial consortia, and grant-backed R&D. Price ranges vary widely by device complexity and care pathway, with hospital procurement and reimbursement shaping total costs of ownership more than list prices bundled service agreements and outcomes-based contracts are increasingly explored. Market trends include miniaturization, battery and driveline innovation, sensor-rich monitoring, and AI-enabled hemodynamic optimization, alongside infection mitigation and anticoagulation management. Opportunities lie in expanding indications to earlier-stage heart failure, enhancing home monitoring, and localized manufacturing/servicing to improve uptime and reduce costs. Latest developments highlight continuous global market growth in artificial heart technologies and Asia-Pacific momentum that influences Australian clinical adoption, while regional cardiovascular device growth informs adjacent capacity for trials, procurement, and service integration in Australia’s hospital systems. Publicly available market trackers and regional reports reflect ongoing segmentation work for Australia’s artificial heart market and a pipeline of competitive benchmarking, signaling active interest from providers and investors in scaling mechanical circulatory support across the country. Partnerships between Australian hospitals and global device makers are expanding clinical trial access, accelerating adoption of next-generation artificial hearts. Local innovators are differentiating through miniaturized designs and biocompatible materials, aiming to reduce complications and broaden patient eligibility.

The Australian artificial heart market segmented by product type into total artificial heart (TAH), ventricular assist devices (VADs), and bioartificial heart systems, it balances established mechanical support with cutting-edge regenerative approaches, and also it reflects the country’s growing focus on advanced cardiac care and innovation in mechanical circulatory support. The total artificial heart segment represents the most ambitious technology, designed to replace the entire function of a failing heart. While still in early stages of adoption, Australian research institutions and hospitals are participating in global clinical trials, exploring compact, magnetically levitated designs that promise long-term durability and physiologic blood flow. This segment is driven by the shortage of donor hearts and the rising prevalence of end-stage heart failure, offering patients a potential alternative to transplantation. Ventricular assist devices (VADs) dominate the current market, serving as bridge-to-transplant or destination therapy for patients with advanced heart failure. Australia’s hospitals widely use VADs from global manufacturers, with innovations focusing on miniaturization, infection control, and wireless energy transfer. Their relatively established regulatory pathway and proven clinical outcomes make VADs the most commercially viable product type, supported by government reimbursement schemes and strong demand in tertiary care centers. The bioartificial heart systems segment is emerging, combining living cells with biocompatible scaffolds to mimic natural cardiac tissue. Australian universities and research groups are collaborating with international partners to advance regenerative technologies, aiming to reduce complications such as clotting and rejection. Though largely experimental, bioartificial systems represent the future of personalized cardiac care, aligning with global regenerative medicine trends.

The Australian artificial heart market, segmented by application into bridge-to-transplant therapy, destination therapy, bridge-to-recovery therapy, and temporary mechanical circulatory assistance, reflects the country’s evolving strategies for managing advanced heart failure and critical cardiac conditions. These segments show Australia’s artificial heart market balances urgent life-saving interventions with long-term therapies, connecting with the global market where bridge-to-transplant remains dominant, destination therapy is expanding, and recovery-focused. In bridge-to-transplant therapy, artificial hearts and ventricular assist devices (VADs) are used to sustain patients awaiting donor organs. With Australia facing limited donor availability, this segment is vital, providing life-saving support and stabilizing patients until transplantation. Hospitals increasingly adopt advanced VADs and investigational total artificial hearts to extend survival and improve transplant readiness. Destination therapy refers to long-term use of artificial hearts or VADs in patients who are not eligible for transplantation. This segment is growing as Australia’s aging population and rising chronic heart disease prevalence increase demand for permanent mechanical circulatory support. Destination therapy emphasizes quality of life, reduced hospitalizations, and integration with home monitoring systems, aligning with cultural trends favoring patient-centric care. In bridge-to-recovery therapy, devices are employed temporarily to allow the native heart to heal after acute injury, such as myocarditis or post-surgical complications. Australian hospitals use short-term VADs and extracorporeal devices to support recovery, with outcomes improving through advances in biocompatible materials and monitoring technologies. Temporary mechanical circulatory assistance is critical in emergency and perioperative settings, providing rapid stabilization during cardiac shock or surgical interventions. Portable extracorporeal pumps and short-term assist devices are widely used in intensive care units, ensuring immediate support when conventional therapies are insufficient.

Australia’s artificial heart market, segmented by end-users such as cardiac surgery centres, specialised heart failure treatment facilities, and transplant centres, reflects the country’s growing investment in advanced cardiovascular care and life-saving technologies. The cardiac surgery centres segment is the largest, driven by Australia’s strong hospital infrastructure and rising incidence of end-stage heart disease. These centres adopt artificial hearts and ventricular assist devices (VADs) as bridge-to-transplant or destination therapies, with global OEMs supplying advanced mechanical circulatory support systems. Their USP lies in surgical expertise, integration of cutting-edge devices, and comprehensive post-operative care. Specialised heart failure treatment facilities represent a rapidly expanding segment, focusing on patients who are not immediate candidates for transplant but require long-term circulatory support. These facilities emphasize patient-centric care, combining artificial heart technologies with monitoring and rehabilitation programs. Their business model often revolves around multidisciplinary teams and partnerships with device manufacturers to provide tailored therapies. The transplant centres segment is critical, as artificial hearts are frequently used as bridge solutions for patients awaiting donor organs. These centres rely on advanced devices to stabilize patients and improve survival rates during long waiting periods. Their USP lies in combining surgical innovation with transplant expertise, supported by government-backed funding and international collaborations. Australia’s aging population, increased prevalence of cardiovascular disease, and government initiatives to strengthen cardiac care infrastructure all enhance the potential of this industry. Current developments include clinical trials of next-generation total artificial hearts, expanded partnerships between Australian hospitals and global OEMs, and investment in telehealth-enabled monitoring, positioning the artificial heart market as a vital and innovation-driven segment of Australia’s healthcare ecosystem.



Considered in this report
•Historic Year: 2020
•Base Year: 2025
•Estimated Year: 2026
•Forecast Year: 2031

Aspects covered in this report
• Australia Artificial Heart Market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Total Artificial Heart (TAH)
• Ventricular Assist Devices (VADs)
• Bioartificial Heart Systems

By Application
• Bridge-to-Transplant Therapy
• Destination Therapy
• Bridge-to-Recovery Therapy
• Temporary Mechanical Circulatory Assistance

By End-User
• Cardiac Surgery Centres
• Specialised Heart Failure Treatment Facilities
• Transplant Centres